BLRX
BioLineRx Ltd.
$2.63
+$0.40(+17.73%)
26
Overall
--
Value
10
Tech
42
Quality
Market Cap
$10.36M
Volume
116.69K
52W Range
$2.15 - $7.77
Target Price
$20.33
Company Overview
| Mkt Cap | $10.36M | Price | $2.63 |
| Volume | 116.69K | Change | +17.73% |
| P/E Ratio | -1.1 | Open | $2.40 |
| Revenue | $22.9M | Prev Close | $2.23 |
| Net Income | $-9.2M | 52W Range | $2.15 - $7.77 |
| Div Yield | N/A | Target | $20.33 |
| Overall | 26 | Value | -- |
| Quality | 42 | Technical | 10 |
No chart data available
About BioLineRx Ltd.
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Sector: Healthcare
Industry: Biotechnology
Latest News
BioLineRx and Hemispherian Dose First Patient in Phase 1/2a GLIX1 Glioblastoma Trial
TipRanks Auto-Generated Newsdesk•14 hours ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BLRX | $2.63 | +17.7% | 116.69K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |